Sector News

Sanofi cancer executive jumps ship to Silicon Therapeutics

October 17, 2017
Life sciences

Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon, becoming the latest in an increasingly long line of Big Pharma executives to join the early-stage life science stream.

Winter comes to the Boston-based company from Sanofi, where since 2013 he led its U.S. oncology research as site lead and research cluster head on overcoming immunosuppression.

This comes as Sanofi has once again been retooling its cancer R&D, bringing a deeper focus into key oncology areas after seemingly looking to scale down just a few years back.

Winter, also a Blueprint Medicines, Merck Research Laboratories and Exelixis alumnus, will work with Silicon and its “integrated physics-based drug discovery,” where it is looking to create small molecule therapeutics for diseases with challenging protein targets that are difficult to drug.

“Silicon Therapeutics has assembled a world-class team applying an industry-leading platform to address fundamental challenges for designing next-generation, breakthrough therapeutics,” said Winter.

“I’m excited to join Silicon Therapeutics’ mission that joins integrated excellence in physics-based simulations, chemistry and disease biology focused on making drugs that matter for patients.”

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

November 21, 2021

Johnson & Johnson to focus on pharmaceuticals

Life sciences

Johnson & Johnson has announced that it plans to separate its Consumer Health business, leaving the new Johnson & Johnson to focus on pharmaceuticals and medical devices. Alex Gorsky, current CEO, will become the Executive Chairman of the new Johnson & Johnson. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, will become the new CEO.

November 21, 2021

Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform

Life sciences

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms applicable across all Novo Nordisk’s therapeutic focus areas.

November 21, 2021

What are the benefits of the digital health revolution?

Life sciences

Naomi predicts that start-ups will continue to take over the healthcare industry, and Big Pharma companies will be forced to adapt to the future by partnering with small tech start-ups, or fade away due to irrelevance. Discover more of industry leader Naomi Fried’s insights as she discusses the future of healthcare with Andrew Kris of Borderless

Send this to a friend